Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation

Summary

This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK and PD of HSK42360 when given orally in patients with active BRAF V600 mutation locally advanced or metastatic Solid Tumors.

Timeline

Start

2024-06-25

Primary completion

2026-08-30

Completion

2027-07-07

Drugs

Indications